MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Revenue
$51,442K
Net Income
-$12,416K
Net Profit Margin
-24.14%
EPS
-$0.08
Unit: Thousand (K) dollars
Revenue Breakdown
North America
EMEA
Asia Pacific
Latin And Central America
Revenue Breakdown
Tri Link Segment
Cygnus Segment
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Revenue
51,442
65,837
49,866
41,630
Cost of revenue
30,792
32,136
37,024
35,975
Gross profit
20,650
33,701
-65,912
5,655
Selling, general and administrative
32,070
29,092
31,583
35,396
Research and development
3,702
3,889
3,788
3,844
Change in estimated fair value of contingent consideration
-
-
-100*
60
Goodwill impairment
0
0
-
0
Impairment of goodwill and long-lived assets
-
-
-49,136*
-
Restructuring
-33
2,878
6,748*
7,386
Total operating expenses
35,739
35,859
-7,117
46,686
Loss from operations
-15,089
-2,158
-58,795
-41,031
Interest expense
4,809
5,749
6,555
6,844
Interest income
1,159
1,873
2,384
2,797
Loss on extinguishment of debt
-3,011
-
0*
-
Change in payable to related parties pursuant to the tax receivable agreement
-
-
0*
0
Other expense
-52
-494
-43
-71
Loss before income taxes
-21,802
-6,528
-63,009
-45,149
Income tax benefit
-171
-151
6
-92
Net loss
-21,631
-6,377
-63,015
-45,057
Net loss attributable to non-controlling interests
-9,215
-2,644
-27,334
-19,501
Net loss attributable to maravai lifesciences holdings, inc
-12,416
-3,733
-35,681
-25,556
Basic EPS
-0.08
-0.02
-0.246
-0.18
Diluted EPS
-0.08
-0.02
-0.246
-0.18
Basic Average Shares
147,996,000
146,426,000
145,096,000
144,683,000
Diluted Average Shares
147,996,000
146,426,000
145,096,000
144,683,000
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
1
2
Net loss
attributable to maravai...
-$12,416K
(68.64%↑ Y/Y)
Net loss
attributable to...
-$9,215K
(69.53%↑ Y/Y)
Tri Link Segment
$24,646K
Cygnus Segment
$6,638K
Tri Link Segment
$6,129K
Cygnus Segment
$4,324K
Cygnus Segment
$5,618K
Tri Link Segment
$3,701K
Cygnus Segment
$193K
Tri Link Segment
$193K
Net loss
-$21,631K
(69.03%↑ Y/Y)
Income tax benefit
-$171K
(96.01%↑ Y/Y)
North America
$31,284K
EMEA
$10,453K
Asia Pacific
$9,319K
Latin And Central
America
$386K
Loss before income
taxes
-$21,802K
(70.59%↑ Y/Y)
Interest income
$1,159K
(-61.75%↓ Y/Y)
Revenue
$51,442K
(8.53%↑ Y/Y)
Loss from operations
-$15,089K
(77.23%↑ Y/Y)
Interest expense
$4,809K
(-29.44%↓ Y/Y)
Loss on
extinguishment of debt
-$3,011K
Gross profit
$20,650K
Other expense
-$52K
(98.72%↑ Y/Y)
Cost of revenue
$30,792K
(-22.30%↓ Y/Y)
Total operating
expenses
$35,739K
(-68.56%↓ Y/Y)
Restructuring
-$33K
Selling, general and
administrative
$32,070K
(-16.86%↓ Y/Y)
Research and development
$3,702K
(-24.17%↓ Y/Y)
Buy us a coffee
MARAVAI LIFESCIENCES HOLDINGS, INC. (MRVI)
MARAVAI LIFESCIENCES HOLDINGS, INC. (MRVI)